Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
Recruiting now · Not applicable · Has a placebo group
Conditions studied: Multiple Sclerosis, Relapsing-Remitting
In brief
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve verbal retrieval in multiple sclerosis patients. The primary outcome measures are neuropsychological assessments of verbal retrieval, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures. Additionally, the study will examine the degree to which baseline assessments of cognition and concussion history predict responses to treatment over time, both on assessments administered within the intervention period and at follow-up.
Key facts
- Study ID
- NCT05958381
- Run by
- The University of Texas at Dallas
- People needed
- 100
- Starts
- 2023-10-18
- Expected to finish
- 2027-06-30
- Last updated by the study team
- 2025-08-14
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- º Diagnosed with relapsing-remitting multiple sclerosis (RRMS)
- º Memory retrieval deficit based on neuropsychological testing done in our lab
- º Must be fluent in speaking and reading English.
You may not qualify if…
- º Relapse or acute MS exacerbation or a course of steroids in the two months preceding the testing
- º Participants using benzodiazepines must have been on a stable dose for at least two months
- º Potentially confounding psychological or neurological disorder, including:
- dementia of any type
- epilepsy or other seizure disorders
- severe traumatic brain injury
- brain tumor
- present drug abuse
- stroke
- blood vessel abnormalities in the brain
- Parkinson's disease
- Huntington's disease
- º inability to give informed consent
- º cranial implants
- º skull defects that affect tDCS administration
- º use of medications that interact with or potentially interact with tDCS effects, including:
- anti-convulsants
- L-dopa
- carbamazepine
- sulpiride
- pergolide
- lorazepam
- rivastigmine
- dextromethorphan
- D-cycloserine
Where it is running
- The University of Texas at Dallas — Richardson, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.